N/A N=30 Trial of Scrambler Therapy or Sham Treatment for Low Back Pain
Low Back Pain
Primary: Worst Low Back Pain Score — 5.4; 4.9; 3.2; 5.8 units on a scale — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=201 Evaluating the Efficacy of an Absorbent Foam Dressing Containing Silver (Mepilex Ag) Versus the Same Dressing Without Silver Used on Subjects With Venous Leg Ulcers or Mixed Ulcers
Venous Leg Ulcers · Mixed Leg Ulcers
Primary: Efficacy Will be Defined as Absolute Wound Size Reduction. — -4.65; -5.09 cm2
Phase 2 N=47 Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3
Hepatitis C
Primary: Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12) — 95.7; 83.3 percentage of participants
Phase 2 N=29 Naltrexone and Hypoglycemia in Type 1 Diabetes
Type 1 Diabetes · Hypoglycemia Unawareness
Primary: Cerebral Blood Flow — 1.7; 1.3 percentage of signal intensity change
Phase 2 N=28 Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir
HIV Infection
Primary: Change From Baseline in HIV DNA in PBMCs at Week 56 — 0.00; 0.04 log^10 copies per 10^6 PBMCs
N/A N=282 Veterans Service Organizations and My HealtheVet (MHV)
Hypertension · Hyperlipidemia · Coronary Artery Disease
Primary: Registration for MHV — 6.7; 12.7; 11.9; 25.0 Percentage of respondents who use MHV
Phase 2 N=44 Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
Lymphoma
Primary: Complete Response Rate After Remission Induction — 66 percentage of participants
Phase 2 N=84 Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV
HIV · Cancer
Primary: Rate of Seroconversion After 1 Dose of Vaccine — 31; 0; 50; 22 percentage of participants
Phase 4 N=59 Application and Effectiveness Analysis of Internet-based Diabetes Prevention Program
Type 2 Diabetes
Primary: Incidence of Type 2 Diabetes Mellitus — 1; 1 participants
N/A N=523 Self-Management of Osteoarthritis
Osteoarthritis
Primary: Pain — 6.01; 5.77; 5.92; 5.84 units on a scale — p=0.007
Phase 2 N=129 A Study of Oral Recombinant Salmon Calcitonin (rsCT) to Prevent Postmenopausal Osteoporosis
Osteopenia
Primary: Percentage Change From Baseline to Week 54 of Lumbar Spine Bone Mineral Density of Active Compared to Placebo. — 1.03; -0.12 percent change — p=0.0265
N/A N=45 Effect of Whole Body Periodic Acceleration on Airway Endothelial Function
Healthy · Smokers · Asthma
Primary: Airway Blood Flow Response to Albuterol — 2.85; -1.43; 17.93; 4.03 μl/min/ml
N/A N=22 Blue Wavelength Light-blocking Glasses in ADHD-Insomnia
Attention Deficit Hyperactivity Disorder · Delayed Sleep Phase Type Circadian Rhythm Sleep Disorder
Primary: Pittsburgh Sleep Quality Index (PSQI) at 2 Weeks After Baseline — 4.54 units on a scale
Phase 4 N=15 Sustiva Levels With Use of a Gel Capsule
HIV · HIV Infections
Primary: Serum Levels of Efavirenz — 5151.11; 4965.08 ng/mL
Phase 2 N=536 Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings
Streptococcal Infections · Gram-Positive Bacterial Infections · Bacterial Infections
Primary: Geometric Mean Concentrations (GMCs) of Antibodies in Maternal Subjects and Infants at Delivery/Birth — 2.07; 2.31; 3.98; 1.01 μg/mL